Compare GLU & IXHL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | GLU | IXHL |
|---|---|---|
| Founded | 2004 | 2001 |
| Country | United States | Australia |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 119.8M | 97.6M |
| IPO Year | N/A | 2024 |
| Metric | GLU | IXHL |
|---|---|---|
| Price | $21.28 | $3.81 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 13.4K | ★ 5.4M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 8.60% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.62 | N/A |
| Revenue | N/A | ★ $12,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $34.11 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $14.07 | $0.11 |
| 52 Week High | $21.69 | $5.17 |
| Indicator | GLU | IXHL |
|---|---|---|
| Relative Strength Index (RSI) | 57.40 | 85.57 |
| Support Level | $17.78 | $0.32 |
| Resistance Level | $21.69 | N/A |
| Average True Range (ATR) | 0.40 | 0.17 |
| MACD | -0.05 | 0.43 |
| Stochastic Oscillator | 39.03 | 72.68 |
Gabelli Global Utility & Income Trust is a non-diversified, closed-end management investment company. The Fund's objective is to seek a consistent level of after-tax total return. It predominantly invests in stocks of companies involved to a substantial extent in providing products, services, or equipment for the generation or distribution of electricity, gas, or water and infrastructure operations, and in equity securities including preferred securities of companies in other industries, in each case in such securities that are expected to pay periodic dividends.
Incannex Healthcare Inc is a clinical stage pharmaceutical company developing medical cannabis products for the treatment of Obstructive Sleep Apnea (OSA), Traumatic Brain Injury (TBI)/Concussion, Rheumatoid Arthritis, Inflammatory Bowel Disease, and Inflammatory Lung Conditions. The company has an Australian license to import, export, and distribute medicinal cannabis products and has launched a line of cannabinoid products. The Company operates and manages its business as one reportable and operating segment, which is the Research and Development of the use of psychedelic medicine and therapies.